Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China

被引:0
|
作者
Yun-Wei Yan [1 ]
Xin-Kui Liu [2 ]
Shun-Xiang Zhang [3 ]
Qing-Feng Tian [1 ]
机构
[1] Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University
[2] Department of Medical Records Management, The First Affiliated Hospital of Zhengzhou University
[3] Department of Epidemiology and Health Statistics and Henan Key Laboratory for Tumour Epidemiology, College of Public Health, Zhengzhou University
关键词
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND Hepatocellular carcinoma(HCC) is a common malignant tumor worldwide. Many regions across the world have issued various HCC diagnosis and treatment protocols to improve the diagnosis and targeted treatment of patients with HCC. However, real-world studies analysing the practice, application value, and existing problems of the China Liver Cancer(CNLC) staging system are scarce.AIM To analyze the current situation and problems associated with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.METHODS We collected the medical records of all patients with HCC admitted to the First Affiliated Hospital of Zhengzhou University from January 1, 2011 to December 31, 2019, and recorded the hospitalization information of those patients until December 31, 2020. All information on the diagnosis and treatment of the target patients was recorded, and their demographic and sociological characteristics, CNLC stages, screening situations, and treatment methods and effects were analyzed. The survival status of the patients was obtained from follow-up data.RESULTS This study included the medical records of 3022 patients with HCC. Among these cases, 304 patients were screened before HCC diagnosis; their early-stage diagnosis rate was 69.08%, which was significantly higher than that of patients with HCC who were diagnosed without screening and early detection(33.74%). Herein, patients with no clinical outcome at discharge were followed up, and the survival information of 1128 patients was obtained. A Cox model was used to analyse independent risk factors affecting overall survival, which were revealed as age > 50 years, no screening, alpha-fetoprotein > 400 ng/mL, Child–Pugh grade B, and middle and late CNLC stages. Based on the Cox model survival analysis, in our study, patients with HCC identified via screening had significant advantages in overall and tumorfree survival after hepatectomy.CONCLUSION Early diagnosis and treatment can be achieved by screening groups at high risk for HCC based on the guidelines; however, real-world compliance is poor.
引用
收藏
页码:859 / 877
页数:19
相关论文
共 50 条
  • [41] Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study
    Zhang, Wei
    Zhang, Bai-Lin
    He, Jian-Jun
    Fan, Jin-Hu
    Li, Jing
    Zhang, Bin
    Yang, Hong-Jian
    Xie, Xiao-Ming
    Tang, Zhong-Hua
    Li, Hui
    Li, Jia-Yuan
    Wang, Shu-Lian
    Qiao, You-Lin
    Huang, Rong
    Zhang, Pin
    GLAND SURGERY, 2021, 10 (01) : 175 - 185
  • [42] Current diagnosis and treatment of acute pancreatitis in China: a real-world, multicenter study
    Sun, Chuandong
    Li, Zhu
    Shi, Zheng
    Li, Guichen
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [43] Diagnosis and treatment of uterine sarcoma A multicenter, real-world study in western China
    Li, Kemin
    Yin, Rutie
    Li, Li
    Wang, Danqing
    Li Li
    Ma, Cailing
    Ren, Qianchuan
    Wang, Guqing
    Fan, Yang
    Zhou, Honggui
    Liu, Zi
    Li, Tao
    Luo, Kunrong
    Kui, Dingqing
    Wang, Jingyi
    MEDICINE, 2021, 100 (51) : E28220
  • [44] Current diagnosis and treatment of acute pancreatitis in China: a real-world, multicenter study
    Chuandong Sun
    Zhu Li
    Zheng Shi
    Guichen Li
    BMC Gastroenterology, 21
  • [45] Bilateral breast cancer in China: A 10-year single-center retrospective study
    Li, Huiping
    Jiang, Hanfang
    Zhang, Ruyan
    Shao, Bin
    Yan, Ying
    Ran, Ran
    Di, Lijun
    CANCER RESEARCH, 2018, 78 (04)
  • [46] A 10-year retrospective study of neonatal lupus erythematous in China
    Yu, Yingfang
    Du, Lizhong
    Pan, Jiarong
    Zheng, Jiyan
    Chen, An
    Chen, Lihua
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2016, 34 (02): : 174 - 178
  • [47] The 10-year journey of non-small cell lung cancer: A real-world experience.
    Jung, Hyun Ae
    Kim, Kyunga
    Chi, Sang Ah
    Yu, Hyeyeon
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] 10-year real-world outcomes with neoadjuvant systemic therapy in non-inflammatory breast cancer
    Kovac, A.
    Cankar, K.
    Dobovisek, L.
    Cavka, L.
    Godina, E.
    Horvat, V. Jeric
    Rajer, M.
    Starman, T.
    Matos, E.
    Borstnar, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S324 - S325
  • [49] Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
    Xiangyu Zhang
    Liang Zeng
    Yizhi Li
    Qinqin Xu
    Haiyan Yang
    Analyn Lizaso
    Xinru Mao
    Ren’an Jin
    Yu Zeng
    Qinglin Li
    Jianbo Wang
    Yang Li
    Yongchang Zhang
    Nong Yang
    Cancer Immunology, Immunotherapy, 2021, 70 : 2517 - 2528
  • [50] Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
    Zhang, Xiangyu
    Zeng, Liang
    Li, Yizhi
    Xu, Qinqin
    Yang, Haiyan
    Lizaso, Analyn
    Mao, Xinru
    Jin, Ren'an
    Zeng, Yu
    Li, Qinglin
    Wang, Jianbo
    Li, Yang
    Zhang, Yongchang
    Yang, Nong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2517 - 2528